74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Palatin Technologies Inc
Closed
0.2 5.26
Overview
Share price change
24h
Min
0.18
Max
0.21
Employees | 30 |
|---|
Recommendations | Buy |
|---|---|
12 Months Forecast | +3233.33% upside |
Next Earnings | 14 May 2025 |
|---|
Market Cap | 4.7M |
|---|---|
Previous open | -5.06 |
Previous close | 0.2 |
Palatin Technologies Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Palatin Technologies Inc Forecast
Price Target
By TipRanks
3233.33% upside
12 Months Forecast
Average 7 USD 3233.33%
High 7 USD
Low 7 USD
Based on 1 Wall Street analysts offering 12 month price targets forPalatin Technologies Inc - Dist in the last 3 months.
Financials
$
About Palatin Technologies Inc
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
